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Essentials
• Corn Trypsin Inhibitor (CTI) is a selective inhibitor of
coagulation Factor XII (FXII).
• Molecular modelling of the CTI-FXIIa complex sug-
gested a canonical inhibitor binding mode.
• Mutagenesis revealed the CTI inhibitory loop and
helices a1 and a2 mediate the interaction.
• This confirms that CTI inhibits FXII in canonical fash-
ion and validates the molecular model.
Summary. Background: Corn trypsin inhibitor (CTI) has
selectivity for the serine proteases coagulation factor XII
and trypsin. CTI is in widespread use as a reagent that
specifically inhibits the intrinsic pathway of blood coagu-
lation but not the extrinsic pathway. Objectives: To inves-
tigate the molecular basis of FXII inhibition by
CTI. Methods: We performed molecular docking of CTI,
using its known crystal structure, with a model of the
activated FXII (FXIIa) protease domain. The interaction
model was verified by use of a panel of recombinant CTI
variants tested for their ability to inhibit FXIIa enzymatic
activity in a substrate cleavage assay. Results: The dock-
ing predicted that: (i) the CTI central inhibitory loop P1
Arg34 side chain forms a salt bridge with the FXIIa S1
pocket Asp189 side chain; (ii) Trp22 from CTI helix a1
interacts with the FXIIa S3 pocket; and (iii) Arg43 from
CTI helix a2 forms a salt bridge with FXIIa H1 pocket
Asp60A. CTI amino acid substitution R34A negated all
inhibitory activity, whereas the G32W, L35A, W22A and
R42A/R43A substitutions reduced activity by large
degrees of 108-fold, 41-fold, 158-fold, and 100-fold,
respectively; the R27A, W37A, W39A and R42A substitu-
tions had no effect. Synthetic peptides spanning CTI
residues 20–44 had inhibitory activity that was three-fold
to 4000-fold less than that of full-length CTI. Conclu-
sions: The data confirm the validity of a canonical model
of the FXIIa–CTI interaction, with helix a1 (Trp22), cen-
tral inhibitory loop (Arg34) and helix a2 (Arg43) of CTI
being required for effective binding by contacting the S1,
S3 and H1 pockets of FXIIa, respectively.
Keywords: corn trypsin inhibitor; factor XII; molecular
docking simulation; serine protease; trypsin.
Introduction
Factor XII is a coagulation factor that circulates in
plasma as an inactive zymogen [1]. Cleavage of the
Arg353–Val354 peptide bond generates the activated form
FXIIa, which has a heavy chain of 50 kDa, connected to
a light chain of 28 kDa by a Cys340–Cys467 disulfide
bridge. The closest homolog of FXII is hepatocyte growth
factor activator (HGFA), which has a very similar
domain organization including a C-terminal serine pro-
tease domain; a proline-rich region is unique to FXII [2–
4]. FXIIa cleaves prekallikrein to generate kallikrein,
which contributes to bradykinin generation [5]. FXIIa
also cleaves FXI to generate activated FXI (FXIa), which
contributes to plasma coagulation [6]. FXII knockout
mice are protected against thrombosis and ischemic
stroke in models of the disease, and it has been proposed
that targeting FXII could result in medicines with a safer
anticoagulation profile than the currently available anti-
coagulants; this has generated interest in developing selec-
tive inhibitors of FXIIa [7,8].
Corn trypsin inhibitor (CTI) or corn Hageman factor
inhibitor is a bifunctional serine protease and a-amylase
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inhibitor [9–14]. It was first isolated from corn in the
1970s, and shown to have inhibitory activity against tryp-
sin [12,15–19]. Subsequently, CTI was shown to potently
inhibit FXIIa and moderately inhibit FXIa with selectiv-
ity over activated FX (FXa), thrombin, and kallikrein
[10,11,14,16,17,20]. CTI is widely used to block the intrin-
sic pathway in ex vivo plasma studies of contact activa-
tion [17,21]. CTI could have utility as a coating agent to
prevent contact activation in catheters [22].
The crystal structure of CTI reveals a central loop
spanning residues 31–38 with an arginine at position 34
[23]. As this loop resembles a protease substrate site, it is
proposed to act as an inhibition loop [23,24]. CTI also
inhibits a-amylase [25], through a site independent from
the central inhibition loop predicted to interact with ser-
ine proteases [10,11], and has antifungal activity [26,27].
The preference of CTI for FXIIa and trysin is different
from what has been determined for other inhibitors such
as ecotin [28], which inhibits FXIIa, FXIa, trypsin, and
thrombin. There are no known co-crystal structures for
CTI with trypsin or FXIIa to explain this. A non-canoni-
cal binding mode has recently been proposed [29], imply-
ing that the inhibition loop of CTI is projected away
from the active site in FXIIa. To understand CTI binding
to and inhibition of FXIIa further, we used existing crys-
tal structures for CTI and the FXII protease to generate
a model for the complex, which we verified by mutagene-
sis of CTI, establishing a canonical model for CTI inhibi-
tion of FXIIa.
Materials and methods
Materials
Full length activated FXIIa (a-FXIIa) and commercial
CTI were obtained from Enzyme Research Laboratories
(Swansea, UK). S2302 (a chromogenic substrate peptide
mimic) was obtained from Chromogenix (Epsom, UK). A
codon-optimized CTI cDNA was obtained from Gen-
Script (Piscataway, NJ, USA). High-purity-grade (> 95%)
synthetic peptides were obtained from GenScript. Purity
was confirmed by reverse-phase HPLC and mass spec-
trometry. DNA primers were obtained from Eurofins
MWG (Ebersberg, Germany).
Docking of CTI and the FXII protease domain
The docking study was based on the available crystal
structures of CTI [23,24] (Protein Data Bank [PDB]:
1BFA and 1BEA) and on the crystal structure of the
FXII protease in a zymogen-like state that we previously
described and termed FXIIac (PDB: 4XE4) and FXIIc
(PDB: 4XDE). To generate a structure for the activated
conformation of the FXIIa protease, a hybrid model of
FXIIa was created with a similar approach to that used
by previous authors [30]. Step 1 used the crystal
structure of closest homolog HGFA (PDB: 1YC0) as a
template in the program SWISS-MODEL [31,32] to generate
coordinates required for the active FXIIa S1 pocket (in-
cluding residues 16–26, 133–147, 179–189, and 190–224;
residue numbers according to the chymotrypsin number-
ing). In step 2, these coordinates were combined with the
coordinates of the crystal structure of FXIIac (PDB:
4XE4) to generate the remainder of the FXIIa protease
(Fig. S1). Unlike previous authors [30], who used the
FXIIc coordinates (PDB: 4XDE), we utilized FXIIac
(PDB: 4XE4), in which the closed H1 pocket is likely to
be the dominant conformation [3]. This model was regu-
larized in COOT, and superposed onto typical activated
protease crystal structures of thrombin, trypsin, FXa and
FXIa to check the positions of key conserved amino
acids such as Asp189 in the S1 pocket and Trp215 in
the S3 pocket, and to confirm that the N-terminal Ile16
is correctly described. This was validated by inspection
of a 4-A crystal structure of the activated b-FXIIa pro-
tease (R. Manna and J. Emsley, unpublished data).
Docking was performed with this FXIIa hybrid model
(referred to as the FXIIa protease) and CTI crystal struc-
tures (PDB: 1BFA and 1BEA, representing Escherichia
coli-expressed and native CTI protein crystal structures at
resolutions of 2.2 A and 1.95 A, respectively), by use of
the program CLUSPRO with default parameters [33–35]. To
test the robustness of the docking algorithm, CTI docking
calculations were performed with the related proteases
trypsin, HGFA, thrombin, FXa, FXIa, activated FIX
(FIXa), and activated FVII (FVIIa) [36]. The top 10
docked complexes were inspected with PYMOL. When the
pose was observed to be canonical (i.e. having the P1
CTI amino acid Arg34 docked into the protease S1
pocket), the relevant ranking position was recorded in
Table S1. The FXIIa–CTI complex was analysed with
PISA [37], and hydrogen bonding and salt bridge interac-
tions are shown in Table S2.
Cloning and site-directed mutagenesis
CTI cDNA was cloned into the pCOLD I-GST vector
[38]. The resulting construct encoded a recombinant
fusion protein composed of a His6 tag, an FXa site, a
glutathione-S-transferase (GST) tag, an HRV3C protease
site, and CTI (recombinant CTI [rec-CTI]). A forward
and reverse primer pair for each of the mutations was
designed with the www.agilent.com/genomics/qcpd tool,
and the mutagenesis was carried out with the Agilent
Technologies (Stockport, UK) site-directed mutagenesis
kit. The mutagenesis was confirmed by restriction analysis
and DNA sequencing.
Expression, purification, and characterization
The relevant CTI construct was transfected into expres-
sion strain Origami 2 (DE3) and grown under antibiotic
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selection at 37 °C until an OD of 0.9 was reached. The
culture was then induced with 500 lM isopropylthiogalac-
toside, and incubated for 16 h at 10 °C. Bacterial pellets
were collected and lysed by sonication in 100 mM sodium
phosphate buffer (pH 7.4), 300 mM NaCl, and 10% glyc-
erol. Purification was performed with Ni2+–nitrilotriacetic
acid agarose column affinity chromatography. Beads were
washed in binding buffer (20 mM sodium phosphate buf-
fer [pH 7.4], 500 mM NaCl, and 20 mM imidazole), and
eluted with binding buffer containing 500 mM imidazole.
The protein concentration was quantified [39] and verified
by equal loading on an SDS-PAGE gel. Where indicated,
protein was purified further by gel filtration chromatogra-
phy in 50 mM Tris-Cl and 150 mM NaCl (pH 7.4) on a
HiLoad 16/600 Superdex 200 preparative grade column
with a fast protein liquid chromatography system (GE
Healthcare, Little Chalfont, UK).
Recombinant CTI and CTI(R34A) (0.15 mg mL1 in
50 mM Tris-Cl, 50 mM NaCl, pH 7.4) were analyzed
against buffer by circular dichroism (CD) spectroscopy
from 190 nm to 260 nm in a Chirascan-plus spectrometer
(Applied Photophysics, Leatherhead, UK) at 20 °C. Sec-
ondary structure was then predicted with CIRCULAR
DICHROISM ANALYSIS USING NEURAL NETWORKS software
[40].
a-FXIIa enzymatic assay
The enzymatic activity of a-FXIIa was measured by mon-
itoring the amount of pNA chromophore released from
substrate H-D-Pro-Phe-Arg-pNA (S-2302). Assays were
performed in a 100-lL volume at 33 °C in 96-well plates
in a Perkin Elmer (Seer Green, UK) Envision plate
reader, and pNA release was followed over a period of
6 h by reading the absorbance at 405 nm. Absorbance
values were converted to pNA concentrations by compar-
ison with a standard curve obtained under exactly the
same instrument conditions. All absorbance values were
within the linear measurement range of the instrument.
Initial rates were calculated on the basis of the first
30 min of incubation. To assess the KM, concentrations
of substrate peptide between 0.1 mM and 0.6 mM were
incubated with 10 nM a-FXIIa, enzymatic activity was
measured as described above, and data were analyzed by
non-linear regression with the Michaelis–Menten algo-
rithm (GRAPHPAD PRISM, version 6.04). To assess the inhi-
bitory mechanism of CTI, 30 nM CTI was incubated with
these same concentrations of substrate peptide, the reac-
tion was initiated by the addition of 10 nM a-FXIIa,
enzymatic activity was measured as described above, and
data were analyzed by non-linear regression with the
Michaelis–Menten algorithm (GRAPHPAD PRISM, ver-
sion 6.04) and by linear regression after Lineweaver–Burk
transformation. To assay inhibitors, concentrations of
CTI variant proteins between 108 M and 105 M or con-
centrations of peptides between 106 M and 103 M were
incubated with 200 lM substrate peptide, the reaction was
initiated by addition of 10 nM a-FXIIa, enzymatic activity
was measured as described above, and IC50 values were
determined by non-linear regression analysis (GRAPHPAD
PRISM, version 6.04) using the log[inhibitor] versus
response – variable slope algorithm with a bottom con-
straint.
Results
Docking of CTI and FXIIa
Previous studies on CTI cleavage by trypsin identified a
scissile bond in CTI between Arg34 and Leu35 [24] . This,
together with sequence similarities between the CTI
region of Arg34 and the activation loop of FXI, the natu-
ral FXIIa substrate (Fig. 1A) [41], indicates that CTI is
likely to be a canonical inhibitor of FXIIa that interacts
with the protease in a similar way to the substrate.
Kinetic analysis of the inhibition of a-FXIIa by CTI
showed a competitive inhibitory mechanism, in line with
this notion (Fig. S3). Kinetic parameters were close to
those reported historically for this enzyme (Fig. S3)
[14,42]. Figure 1B shows an early crystal structure of a
canonical interaction between the peptidic inhibitor
PPACK and thrombin [43]; however, a non-canonical
model of FXIIa inhibition by CTI has recently been pro-
posed [29]. To investigate this, we first produced a homol-
ogy model of the FXIIa protease, and then performed
molecular docking in CLUSPRO, employing this homology
model together with the established CTI crystal structures
[23,24].
Inspection of the top-ranked docking solution identified
a canonical complex whereby the CTI residue Arg34 was
inserted into the S1 pocket of FXIIa for both CTI crystal
structures, with scores of  999.6 and  1007.9 and with-
out steric clashes (Fig. 1C shows 1BFA, which is illus-
trated in stereo in Fig. S2 and Movies S1 and S2). For
comparison and to establish the stability of the CLUSPRO
docking algorithm, we performed similar docking of CTI
with the crystal structures of the protease domains from
trypsin, HGFA, thrombin, FXa, FXIa, FIXa, FVIIa, and
kallikrein. In each case, the top 10 lowest-energy solu-
tions were inspected in PYMOL for canonical complexes in
which the Arg34 occupies the S1 binding pocket. The
ranked position observed is indicated in the c-rank col-
umn of Table S1. Dockings for trypsin and HGFA with
the CTI structure 1BFA gave ranking scores of  815.6
and  941.5, respectively, for the canonical complex. As
CTI is a known trypsin inhibitor, this result is consistent
with previous observations. To our knowledge, inhibition
of HGFA by CTI has not been assessed directly. For
thrombin and FXIa, a canonical docking pose with CTI
was also observed, but only for CTI structure 1BEA, and
inspection of these docking solutions revealed steric
clashes. This is consistent with previous reports that CTI
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weakly inhibits FXIa and does not inhibit thrombin
[14,29]. Of all the proteases investigated, FXIIa was the
only canonical top-ranked docking solution for both CTI
structures 1BFA and 1BEA, and the values of energy
were more significant than with any of the other solutions
in the study (Table S1).
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Fig. 1. Docking of the activated factor XII (FXIIa)–corn trypsin inhibitor (CTI) complex. (A) The canonical inhibitor sequence of CTI loop
residues 30–38 is shown aligned to the sequences of the activation loops of FXI, prekallikrein, and FXII which are natural substrates for FXIIa
cleavage, and the sequence of peptidomimetic thrombin inhibitor PPACK. (B) Cartoon diagram showing the canonical inhibitor PPACK bind-
ing into the S1 pocket of thrombin prepared by use of the crystal structure with Protein Data Bank code 1PPB with PYMOL. (C) Cartoon dia-
gram of the docked FXIIa–CTI complex. FXIIa is in gray and CTI is in cyan. Key residues are shown as sticks, and interactions are indicated
as purple dotted lines. The top boxed area is a zoom-in of the area of the FXIIa S1, S2 and S3 pockets (gray) and CTI (cyan), and the right-
hand boxed area is the front of the S1 pocket and the FXIIa H1 pocket residue D60 shown interacting with CTI (residue number D60 corre-
sponds to FXII Asp397 and Asp416 in sequence numbering without and with the signal peptide, respectively, or FXII Asp60A from chy-
motrypsin numbering).
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Structure of the FXIIa protease–CTI complex
Figures 1B and 2 show a cartoon diagram of the struc-
ture of the FXIIa–CTI docked complex, and Table S2
shows the electrostatic and hydrogen bonding interactions
at this interface. The interactions involve salt bridges,
hydrogen bonds and hydrophobic interactions burying a
total surface area of 1102 A2 (PDBE-PISA). The Arg34 side
chain extends into the S1 pocket of the FXIIa catalytic
domain, forming a salt bridge with the S1 pocket residue
Asp189 side chain carboxyl (chymotrypsin numbering
used) (Figs. 1B and 2; Movie S1). A nitrogen atom from
the Arg34 guanidinium group forms a hydrogen bond
with the FXIIa Gly218 carbonyl. The main chain
carbonyl oxygen of Arg34 forms hydrogen bonds with
the main chains of Gly193 and Ser195 in the FXIIa
oxyanion hole. In addition, the side chain hydroxyl group
of Ser195 from the catalytic triad contacts the Arg34 car-
bonyl. Additional interactions flanking the P1 Arg34
include Pro33 interacting with the S2 pocket, and the
Leu35 side chain forming hydrophobic contacts with the
FXIIa S10 pocket (Fig. 1B; Movie S1). The interactions
of CTI residues Gly32 and Pro33 with the FXIIa S2
pocket are similar to interactions observed in other serine
protease complex crystal structures with the
chloromethylketone inhibitor PPACK [43] (which has the
peptidomimetic sequence PheProArg) and protein inhibi-
tors such as infestin-1 [44].
FXIIa model
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S1 pocket
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Fig. 2. Charge surface representations of the activated factor XII (FXIIa)–corn trypsin inhibitor (CTI) interaction (blue = positive, red = nega-
tive). (A) The FXIIa model is shown with the key surface pockets labeled. (B) Docked complex of FXIIa (shown as a cartoon in gray) and
CTI shown as a transparent charged surface illustrating the basic region interacting with the negatively charged S1 (D189) and H1 (D60) resi-
dues shown as sticks. (C) FXIIa protease as viewed in (A) but with CTI residues 20–44 shown as a cartoon in cyan, with key residues labeled
as sticks in cyan.
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Loss of a-FXIIa inhibition for CTI mutant R34A
To test the predictions of the model above, we produced
rec-CTI and utilized mutagenesis to generate 12 variants
with amino acid substitutions at the predicted FXIIa–CTI
interface (Fig. 3A). rec-CTI and a commercial prepara-
tion of CTI inhibited a-FXIIa in identical ways, with
pIC50 values of 6.94  0.04 and 6.95  0.05, respectively
(Fig. 3B; Table 1). GST, the main fusion partner of CTI
in this construct, did not inhibit a-FXIIa. Substitution of
Arg34 of CTI, at the P1 substrate site, with Ala (R34A)
caused complete loss of inhibition of a-FXIIa, even at
high protein concentrations (Figs. 4 and 5; Table 1). CD
spectroscopy revealed no differences between wild-type
and rec-CTI(R34A), with the expected 58% a-helix sec-
ondary structure being present in both (Fig. S4). Gel
filtration of wild-type and rec-CTI(R34A) revealed that
the majority of the proteins appeared as monomers, with
a smaller proportion eluting at a size consistent with a
dimeric form, most likely because of dimer formation at
the GST moiety, with no protein aggregates being visible
(Fig. S5). Like the original preparation, the gel-filtrated
monomeric form of rec-CTI(R34A) was still not able to
inhibit a-FXIIa protease activity, whereas wild-type rec-
CTI inhibited a-FXIIa in a similar fashion as the non-
gel-filtrated protein (Fig. S5). Thus, the lack of inhibitory
activity of the R34A mutant was not attributable to loss
of protein because of aggregation. This confirms that
Arg34 plays a central role in the binding of CTI to
FXIIa, and is consistent with the docking showing that
Arg34 undergoes the greatest number of interactions with
the FXIIa protease (Figs 1B and 2; Table S2) [23,24].
CTI substitutions W22A, G32W, L35A and R43A reduce its
inhibitory activity
Alanine substitution of Trp22 in rec-CTI resulted in a
158-fold reduction in inhibitory activity, showing that it
makes a significant contribution to FXIIa binding (Figs 4
and 5; Table 1). This further validates the docking model
shown in Fig. 1B, whereby the CTI Trp22 aromatic side
chain undergoes a p–p stacking interaction with the
FXIIa Tyr99 side chain, and the Trp22 side chain nitro-
gen atom contacts the Pro96 carbonyl of the cation hole
in the S3 pocket. The R42A/R43A double mutant had
100-fold lower activity than wild-type CTI. This appears
to be mostly attributable to the R43A substitution, as the
activity of the R42A mutant was comparable to that of
the wild type. This is compatible with our model, which
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Fig. 3. Expression of recombinant corn trypsin inhibitor (CTI)
mutants and activated factor XII (a-FXIIa) activity in the presence
of recombinant CTI (rec-CTI), commercial CTI, and glutathione-S-
transferase (GST). (A) Wild-type CTI or mutants were expressed as
His-GST fusion proteins, as explained in Materials and methods.
Purified proteins were quantified by the Lowry method, and 1 lg of
protein was analyzed by SDS-PAGE followed by Coomassie blue
staining. (B) CTI samples (108 M to 105 M) were incubated with
200 lM substrate peptide, and this was followed by addition of
a-FXIIa; enzymatic activity was then monitored as described in
Materials and methods. Data points were fitted to a curve by non-
linear regression (GRAPHPAD PRISM 6.04; log[inhibitor] versus
response – variable slope algorithm with a bottom constraint). Error
bars indicate the standard error (n = 3–5 independent observations).
Table 1 Inhibition of activated factor XII by corn trypsin inhibitor
(CTI), and recombinant CTI variants. pIC50 values are given with
the standard error (SE) of the fit (n = 3–5 independent experiments).
For reference, the corresponding IC50 is also given, as is the fold
reduction in inhibitory activity of each mutant as compared with
inhibition by recombinant CTI (rec-CTI)
Protein pIC50  SE IC50 (M) Fold
CTI 6.97  0.04 1.1 9 107
rec-CTI 6.94  0.05 1.2 9 107 1
GST NIA NIA –
W22A 4.72  0.24 1.9 9 105 158
R27A 6.78  0.04 1.7 9 107 1
G30W 6.32  0.06 4.8 9 107 4
G32W 4.89  0.06 1.3 9 105 108
R34A NIA NIA –
L35A 5.31  0.05 4.9 9 106 41
W37A 6.97  0.06 1.1 9 107 1
E39A 6.85  0.06 1.4 9 107 1
R42A 6.72  0.15 1.9 9 107 2
R42A/R43A 4.98  0.02 1.1 9 105 100
R27A/E39A 6.58  0.08 2.6 9 107 2
R27A/R42A 6.80  0.05 1.6 9 107 1
GST, glutathione-S-transferase; NIA, no inhibitory activity was
observed.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
6 B. K. Hamad et al
shows that Arg43 forms a salt bridge with FXIIa
Asp60A, which would be lost in the R43A mutant (the
Asp60A numbering is based on homology with chy-
motrypsin, with the letter A referring to the first residue
of a three-residue insertion present in FXII but not in
chymotrypsin [45]; this residue number corresponds to
FXII Asp397 without and Asp416 with the signal peptide,
and is labeled as D60 in Figs 1 and 2).
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Fig. 4. Inhibition of activated factor XII (a-FXIIa) by recombinant corn trypsin inhibitor (rec-CTI) variants and peptides. Concentrations of
rec-CTI variants (108 M to 105 M) or peptides (106 M to 103 M) were incubated with 200 lM substrate peptide, and this was followed by
addition of a-FXIIa; enzymatic activity was then monitored as described in Materials and methods. pIC50 values were obtained by non-linear
regression (GRAPHPAD PRISM 6.04; log[inhibitor] versus response – variable slope algorithm with a bottom constraint). Error bars indicate the
standard error (n = 3–5 independent observations).
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Replacement of Gly32 with tryptophan resulted in a
108-fold reduction in the inhibitory activity of rec-CTI
(Fig. 4; Table 1). Figure 1B shows that the Gly32 main
chain nitrogen forms an antiparallel b-strand hydrogen
bond with the FXII Gly216 carbonyl, and this close asso-
ciation is probably disrupted by the introduction of the
bulky tryptophan side chain, which may also disrupt con-
tacts made in the S3 pocket by CTI residues Ile31 and
Trp22. For comparison, replacement of Gly30 with a
tryptophan resulted in only a four-fold reduction in inhi-
bitory activity (Fig. 4; Table 1). Finally alanine
substitution of Leu35 (L35A) resulted in a 41-fold reduc-
tion in the inhibitory activity of rec-CTI (Fig. 4; Table 1).
This is probably attributable to the loss of hydrophobic
interactions with the FXIIa protease S10 pocket, as ala-
nine has an unbranched Cb.
CTI substitutions R27A, W37A, E39A, R42A do not affect its
activity
Alanine substitution of Arg27, Trp37, Glu39 and Arg42 in
rec-CTI did not affect its inhibitory activity, and the
mutants behaved in an identical fashion to the wild type
(Figs 4 and 5; Table 1). To further confirm that these resi-
dues make a limited contribution to the activity, R27A/
E39A and R27A/R42A double substitutions were per-
formed, and these did not influence rec-CTI activity either
(Figs. 4 and 5; Table 1). This indicates that Arg27, Trp37,
Glu39 and Arg42 are unlikely to contribute to the inter-
face. For Arg27, this is consistent with the docking pose, as
this residue is on the opposite side of the CTI structure to
the predicted interface. However, it rules out a more unli-
kely inverted CTI orientation, which some docking poses
suggested could be possible. CTI residues Glu39 and
Arg42 form an internal salt bridge in helix a2 and,
although the docking predicts a potential hydrogen bond
between Arg42 and the FXII Ser40 side chain, the lack of
effect of the E39A and R42A substitutions suggests that
these do not contribute to CTI inhibition. The Trp37 side
chain nitrogen is predicted to form a hydrogen bond with
the Gln192 side chain, but replacement of Trp37 with an
alanine did not affect enzyme inhibition, indicating that
this residue makes little or no contribution to the interface.
Loss of activity of inhibition loop-based peptides
The above studies revealed the importance of the 24-resi-
due stretch Cys20–Cys44 of CTI to the interaction with
FXIIa. We employed synthetic peptides from this region
to assess whether these had any inhibitory activity against
S3 S2 S1 S1' H1
44
α2
α2
α1
α1
R43
C44
C20
W22
I31
G30
R27
R34
L35
E39
R42
W37
R34
20
FXIIa pocketA
B C
Fig. 5. Corn trypsin inhibitor (CTI) substitutions affect inhibition of
activated factor XII (FXIIa) to different degrees. (A) The CTI
amino acid sequence for residues 20–44 with the respective contact
pockets in FXIIa indicated above. (B) Cartoon diagram of the CTI
structure showing residues affected by the mutagenesis experiments.
(C) Close-up view of the structure of CTI residues 20–44. Color cod-
ing in B and C: Red – essential for binding; Green – important for
binding; Orange – contributes to binding.
Table 2 Inhibition of activated factor XII (a-FXIIa) by synthetic peptides based on the central inhibition loop of corn trypsin inhibitor (CTI).
Concentrations of inhibitory peptide between 106 M and 103 M were incubated with substrate peptide, and this was followed by addition of
a-FXIIa. The initial rate of substrate conversion was determined by following the release of pNA colorimetrically. Data were analyzed by non-
linear regression in GRAPHPAD PRISM 6.04 with the log[inhibitor] versus response – variable slope algorithm with a bottom constraint. pIC50 val-
ues are indicated with the standard error (SE) of the fit (n = 3–5 independent experiments). For reference, the corresponding IC50 is also given,
as is the fold reduction in inhibitory activity of each mutant as compared with inhibition by recombinant CTI (rec-CTI)
Peptide pIC50  SE IC50 (M) Fold
rec-CTI (full-length reference) 6.94  0.05 1.2 9 107 1
CTI(20–44): CRWYVTSRTAGIGPRLPWPELKRRC 3.54  0.15 2.9 9 104 2416
CTI(21–43): RWYVTSRTAGIGPRLPWPELKRR 3.34  0.15 4.6 9 104 3833
CTI(23–43): YVTSRTAGIGPRLPWPELKRR 2.94  0.05 1.1 9 103 9166
CTI(21–42): RWYVTSRTAGIGPRLPWPELKR 3.70  0.04 2.0 9 104 1667
CTI(31–38): IGPRLPWP NIA NIA –
Scrambled: GISTAGPWRRRPPELLKVTY NIA NIA –
NIA, no inhibitory activity was observed.
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a-FXIIa. A synthetic peptide spanning Cys20–Cys44 and
similar peptides lacking N-terminal or C-terminal residues
were between three and four orders of magnitude less
potent than full-length rec-CTI (Fig. 4; Table 2). An
eight-mer peptide spanning the loop between helices a1
and a2 (CTI residues 31–38) but containing Arg34 did
not have any inhibitory activity (Fig. 4; Table 2). Thus,
loss of inhibitory activity was observed when the CTI
structure was truncated, with no activity being retained in
a core sequence even though critical residues defined by
mutagenesis were represented. Weak inhibitory activity of
the isolated CTI peptides as compared with the whole
protein indicates that the entire CTI protein is required
for inhibition. The angle between two a-helices is likely to
play an important role in the interaction with FXIIa.
Discussion
To investigate the unique protease inhibitory and selectiv-
ity properties of CTI, we describe a canonical docked
complex of FXIIa and CTI. The model is consistent with
the competitive mechanism by which CTI inhibits a-
FXIIa. To test the veracity of the model in more detail,
we expressed and purified recombinant variants of CTI,
substituting key residues predicted to be important for
formation of the interface with FXIIa. These confirm the
essential role of the canonical P1 residue Arg34, and
establish for the first time the importance of the more
remote residues Trp22 and Arg43 in CTI a-helices 1 and
2. The docking solution is not consistent with a previ-
ously reported non-canonical docking solution [29], which
places CTI at a different location on the surface of
FXIIa. Differences in the methodology between the two
studies are that, in the current study, a hybrid model of
the FXIIa structure was used as opposed to a purely
HGFA-derived homology model [29]. It is likely that the
accurate placement of FXIIa residue Asp60A in the
hybrid FXIIa model plays a role in improving the dock-
ing as compared with the HGFA-derived homology
model. However, the current canonical model is consis-
tent with experimental observations that disruption of the
cysteine loop structure of CTI affects its inhibition of
FXII [29], whereby the function of the cysteine loops
would primarily be to provide the three-dimensional con-
text for the conformation of the inhibitory loop of CTI.
The canonical docking pose that we observed for
FXIIa–CTI is similar to the trypsin–CTI and HGFA–
CTI complexes predicted by CLUSPRO, albeit that there are
fewer interactions overall for trypsin and HGFA, owing
to Asp60A (H1 pocket) being absent in these proteases.
Superposition of FXIIa and trypsin revealed a striking
similarity in the main chain conformation of the 99-loop
between FXIIa and trypsin that is not seen in other pro-
teases (Fig. 6A), albeit that the FXIIa residue Tyr99 is
replaced by Leu99 in trypsin. CTI does not inhibit kallik-
rein, FIXa, and FVIIa [17], and, consistent with this, the
docking failed to place CTI Arg34 in the S1 pocket for
any of the top 10 solutions examined (Table S1).
Although the docking with the FXa protease did produce
a solution with CTI Arg34 projecting into the S1 pocket,
the Arg34 side chain does not fully enter the pocket and
no salt bridge was formed with FXa Asp189, owing to
steric clashes around the S1, S2 and S3 pockets. Examina-
tion of the CTI–thrombin docked complex revealed that,
although Arg34 forms a salt bridge with Asp189, there
are steric clashes between CTI and thrombin amino acid
side chains in the region of the front of the S1 and S3
pockets; a similar situation was observed for FXIa. One
final similarity between FXIIa and trypsin is in the region
of the S10 pocket, where Tyr151 is present in both
D189
Q192
Y151 S195 W37
S3 99-loop FXII, trypsin FXI, FX, FII, FIX, FVII
S1 S1
S1' S3 S3R34
R34CTI
CTI
S1
S1'
A B C
Fig. 6. A model for corn trypsin inhibitor (CTI) protease selectivity. (A) Superposition of the activated factor XII (FXIIa) model (purple) and
trypsin (gray) shown as a Ca backbone in the region of the S1 and S3 pockets, illustrating the main chain similarity of the 99-loop. Key side
chains are shown as sticks for trypsin (orange) and FXIIa (purple). (B) A combination of features around the S1 and S3 pockets are more open
for the bulky CTI inhibitor to bind, with shape changes in the S1 and S3 pockets of other proteases preventing binding of CTI by steric
occlusion.
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proteases (as well as in HGFA); it is absent in the other
coagulation proteases. The area of the S10 pocket is
hydrophobic in character, with contributions from the
side chain of Trp37, and this is utilized by Leu35 of CTI.
Our data indicate that several factors contribute to CTI
selectivity for FXIIa over other coagulation proteases,
including: (i) the open shape of the S1, S10 and S3 pock-
ets, accommodating the bulky helical structure of CTI
around the P1 Arg34 (Fig. 6B); and (ii) FXIIa side chains
Asp60A and Tyr151 in the area of the S10 pocket, which
are missing in other coagulation proteases. A recently
described antibody, 3F7, which binds to the FXII pro-
tease domain has been shown to be an effective anticoag-
ulation agent [46]. This antibody binds via Asp60A, as
mutation of this residue to lysine negated 3F7 antibody
binding. Another well-characterized protein inhibitor of
FXII that selectively blocks the intrinsic pathway of coag-
ulation is the kissing bug protein infestin-4, although the
molecular basis for its selectivity is unknown. Infestin-4,
expressed as an albumin fusion, provides an effective
treatment in murine models of stroke without causing a
bleeding side effect [47,48].
This study used molecular modeling to predict FXIIa–
inhibitor interactions. The fact that experimental data can
be explained logically by this model underlines its valid-
ity. This model could thus be used as a starting point for
rational inhibitor design for the treatment of thrombotic
cardiovascular disease.
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